Titan Medical Expands Global Intellectual Property Portfolio to 30 Patents Issued & 75 Pending with Receipt of First Patent i...
27 Fevereiro 2019 - 11:02AM
Business Wire
Titan Medical Inc. (TSX: TMD) (Nasdaq: TMDI) (“Titan” or the
“Company”), a medical device company focused on the design and
development of a robotic surgical system for application in
minimally invasive surgery (“MIS”), announces that its global
intellectual property portfolio has increased to 30 issued patents
and 75 pending applications through the recent granting and filing
of patent applications directed at aspects of its innovative
robotic surgery program. Included in the recent patent grants is
the Company’s first patent in China titled “Articulated Tool
Positioner and System Employing Same,” for which the Company
announced a notice of allowance in December 2018
The recently granted Chinese patent describes the smooth and
continuously curved articulation of a robotic instrument to
position and orient an end-effector in multiple degrees of freedom.
The continuous curve architecture was designed to provide several
advantages, including facilitating a central lumen that extends
through the instrument to enable an independent roll of the
end-effector, and providing for a multitude of end-effectors and
advanced tools. Corresponding patents have been granted in Europe,
Canada and Japan, and further applications are pending in several
countries including the U.S.
“The continued expansion of our intellectual property portfolio
further strengthens Titan’s position as an innovative leader in
single-port robotic surgery technology,” commented David McNally,
President and CEO of Titan Medical. “I commend Jasminder Brar, our
Director of Strategic Development and Intellectual Property, on
formulating and leading the successful execution of our IP strategy
to enable Titan to protect its intellectual property in major
markets around the world.
“While our initial focus for commercialization is the U.S., we
remain committed to protecting our intellectual property in major
markets to secure the long-term potential of the global surgical
robotics opportunity for Titan or any commercial partners. We
believe our system offers advanced technology in single-port
robotic surgery, which could ultimately play a substantial role in
expanding robotic surgery with the goal of improving patient
outcomes,” he added.
About Titan Medical Inc.
Titan Medical Inc. is focused on computer-assisted robotic
surgical technologies for application in minimally invasive
surgery. The Company is developing the SPORT Surgical System, a
single-port robotic surgical system comprised of a
surgeon-controlled patient cart that includes a 3D high-definition
vision system and multi-articulating instruments for performing MIS
procedures, and a surgeon workstation that provides an advanced
ergonomic interface to the patient cart and a 3D endoscopic view
inside the patient’s body. Titan intends initially to pursue
focused surgical indications for the SPORT Surgical System, which
may include one or more of gynecologic, urologic, colorectal or
general abdominal procedures.
For more information, please visit the Company’s website at
www.titanmedicalinc.com.
Forward-Looking Statements
This news release contains “forward-looking statements” which
reflect the current expectations of management of the Company’s
future growth, results of operations, performance and business
prospects and opportunities. Wherever possible, words such as
“may”, “would”, “could”, “will”, “anticipate”, “believe”, “plan”,
“expect”, “intend”, “estimate”, “potential for” and similar
expressions have been used to identify these forward-looking
statements. These statements reflect management’s current beliefs
with respect to future events and are based on information
currently available to management. Forward-looking statements
involve significant risks, uncertainties and assumptions. Many
factors could cause the Company’s actual results, performance or
achievements to be materially different from any future results,
performance or achievements that may be expressed or implied by
such forward-looking statements, including, without limitation,
those listed in the “Risk Factors” section of the Company’s Annual
Information Form dated March 31, 2018 (which may be viewed at
www.sedar.com). Should one or more of these risks or uncertainties
materialize, or should assumptions underlying the forward-looking
statements prove incorrect, actual results, performance or
achievements may vary materially from those expressed or implied by
the forward-looking statements contained in this news release.
These factors should be considered carefully, and prospective
investors should not place undue reliance on the forward-looking
statements. Although the forward-looking statements contained in
the news release are based upon what management currently believes
to be reasonable assumptions, the Company cannot assure prospective
investors that actual results, performance or achievements will be
consistent with these forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190227005522/en/
LHA Investor RelationsKim Sutton Golodetz(212)
838-3777kgolodetz@lhai.comorBruce Voss(310)
691-7100bvoss@lhai.com
Titan Medical (NASDAQ:TMDI)
Gráfico Histórico do Ativo
De Fev 2024 até Mar 2024
Titan Medical (NASDAQ:TMDI)
Gráfico Histórico do Ativo
De Mar 2023 até Mar 2024